{"url_path":"/sec/nvax/8-k/2026-02-26/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-02-26","source_url":"https://www.sec.gov/Archives/edgar/data/1000694/0001000694-26-000011-index.html","accession_number":"0001000694-26-000011","cik":"0001000694","ticker":"NVAX","issuer_name":"NOVAVAX INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1000694/0001000694-26-000011-index.html","primary_entity_key":"0001000694","primary_entity_name":"NOVAVAX INC"},"word_count":54,"has_tables":true,"body_markdown":"Item 2.02. Results of Operations and Financial Condition.\n\n \n\nThird Quarter Financial Results\n\n \n\nOn February 26, 2026, Novavax, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended December 31, 2025. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K."}